cobicistat · Gilead Sciences Inc · NDA 203094
Tybost
Earliest generic entry, as listed · earliest of 2 marketed strengths
6 Apr 2033
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10039718 (pediatric extension).
Listed patents · 2 unexpired
4 Orange Book listing rows for 2 patents, including 2 pediatric extensions. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 10039718 | drug product | 6 Apr 2033 |
| US 10039718 listing row | drug product | 6 Oct 2032 |
| US 10039718 listing row | pediatric extension · sets the listed date | 6 Apr 2033 |
| US 8148374 | drug substance, drug product, use U-1279 | 3 Mar 2030 |
| US 8148374 listing row | drug substance, drug product, use U-1279 | 3 Sep 2029 |
| US 8148374 listing row | pediatric extension | 3 Mar 2030 |
Exclusivities · 2 unexpired
| NPP | new patient population | 20 Jun 2028 |
| NS | new strength | 20 Jun 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203094 · 001 · RLD · discontinued | tablet, oral | 150MG | 6 Apr 2033 |
| 203094 · 002 · RLD · discontinued | tablet, oral | 90MG | 6 Apr 2033 |
Expired or delisted (1)
- ODE-260 · 22 Aug 2026